Elinzanetant approved as first dual NK-1 and NK-3 blocker for menopausal hot flashes
A new drug profile describes elinzanetant as the first dual NK-1 and NK-3 receptor antagonist approved for moderate to severe ...
A new drug profile describes elinzanetant as the first dual NK-1 and NK-3 receptor antagonist approved for moderate to severe ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine